UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $32.13 Million Stock Position in Repligen Corporation $RGEN

Key Points

• UBS AM has increased its stake in Repligen Corporation by 7.3%, now owning approximately 0.45% of the company, worth $32.1 million.
• Repligen's shares opened at $113.74, with a market capitalization of $6.40 billion, but the company recorded a miss in earnings per share, reporting $0.37 against the estimate of $0.40.
• Several analysts have issued mixed ratings for Repligen, with target prices ranging from $135.00 to $180.00, and an average rating of "Moderate Buy."

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 7.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 252,497 shares of the biotechnology company's stock after acquiring an additional 17,154 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.45% of Repligen worth $32,128,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in RGEN. KBC Group NV boosted its holdings in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock valued at $324,000 after acquiring an additional 329 shares during the period. Harvest Fund Management Co. Ltd bought a new stake in shares of Repligen in the first quarter worth $132,000. XTX Topco Ltd lifted its position in Repligen by 34.2% during the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock valued at $1,646,000 after purchasing an additional 3,295 shares in the last quarter. GAMMA Investing LLC grew its holdings in Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock valued at $122,000 after buying an additional 274 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its stake in shares of Repligen by 233.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock valued at $1,172,000 after buying an additional 6,448 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Shares of RGEN stock traded down $2.08 on Friday, reaching $122.30. The company had a trading volume of 1,103,283 shares, compared to its average volume of 738,209. The stock has a market capitalization of $6.88 billion, a PE ratio of -489.18, a price-to-earnings-growth ratio of 2.29 and a beta of 1.07. The business's 50-day moving average is $119.78 and its 200 day moving average is $126.72. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. During the same quarter in the prior year, the business earned $0.40 earnings per share. Repligen's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Martin D. Madaus bought 1,800 shares of the company's stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on RGEN shares. Wells Fargo & Company dropped their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. Evercore ISI cut their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Finally, Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $166.67.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.